Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes IMVT-1401 targets the neonatal Fc receptor (FcRn). Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes IMVT-1401 targets the neonatal Fc receptor (FcRn).
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 24, 2025 NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.915 | -8.34786399303 | 22.94 | 23.59 | 20.62 | 1401345 | 22.00200725 | CS |
4 | -3.785 | -15.2559451834 | 24.81 | 25.61 | 20.62 | 1251321 | 23.08837792 | CS |
12 | -9.735 | -31.6482444733 | 30.76 | 31.65 | 20.62 | 1030136 | 25.43740694 | CS |
26 | -5.365 | -20.3296703297 | 26.39 | 34.47 | 20.62 | 930218 | 27.73815397 | CS |
52 | -13.235 | -38.6310566258 | 34.26 | 39.55 | 20.62 | 1034937 | 29.0909564 | CS |
156 | 14.545 | 224.459876543 | 6.48 | 45.58 | 3.145 | 1081188 | 24.73850709 | CS |
260 | 5.285 | 33.5768742058 | 15.74 | 53.75 | 3.145 | 945531 | 22.59692704 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales